United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - nifedipine - modified-release tablet - 10mg

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - candesartan cilexetil 16mg;  ; hydrochlorothiazide 12.5mg - tablet - 16/12.5mg - active: candesartan cilexetil 16mg   hydrochlorothiazide 12.5mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate maize starch triethyl citrate - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - candesartan cilexetil 8mg;  ; hydrochlorothiazide 12.5mg - tablet - 8/12.5mg - active: candesartan cilexetil 8mg   hydrochlorothiazide 12.5mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate maize starch triethyl citrate - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

India - English - Central Drugs Standard Control Organization

neiss - losartan pot.,hydrochlorothiazide - tab - 50,12.5;mg - 10

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - nifedipine - modified-release tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - nifedipine - modified-release tablet - 30mg

India - English - Central Drugs Standard Control Organization

neiss - losartan pot. - tab - 50mg - 10

Philippines - English - FDA (Food And Drug Administration)

metro drug, inc.; distributor: metro drug, inc. - norepinephrine (as bitartrate) - concentrate solution for iv infusion - 2mg/ ml

Australia - English - Department of Health (Therapeutic Goods Administration)

lawley pharmaceuticals pty ltd - testosterone, quantity: 10 mg/ml - cream - excipient ingredients: almond oil; butylated hydroxytoluene; carbomer 940; cetomacrogol 1000; cetostearyl alcohol; citric acid; dl-alpha-tocopheryl acetate; trolamine; purified water; phenoxyethanol; propyl hydroxybenzoate; ethyl hydroxybenzoate; isobutyl hydroxybenzoate; butyl hydroxybenzoate; methyl hydroxybenzoate - androfeme 1 is indicated for the treatment of hypoactive sexual desire dysfunction (hsdd) in postmenopausal women. therapeutic intervention with androfeme 1 should only be initiated in women following failure of appropriate education and correction of modifiable biopsychosocial factors (which may include neuroendocrine imbalance, physical ill health or disease, interpersonal difficulties, psychological distress or specific cultural or religious beliefs), according to the international society for the study of women?s sexual health (isswsh) process of care (see figure 1).

European Union - English - EMA (European Medicines Agency)

warner chilcott uk ltd. - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - intrinsa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.